Abstract: Objective To evaluate the clinical outcome of autologous hemopoietic stem cell transplantation(AHSCT) for hematological malignancies. Methods Data of 30 patients with hematological malignant diseases who under went AHSCT in Xuanwu hospital from January 1996 to January 2007 were retrospectively analyzed. There were 14 males and 16 females, the median age was 40(19～52) years. Twenty-five of them had acute non-lymphoblastic leukemias(ANLL)(CR₁ 24, CR₂ 1), 4 had acute lymophblastic leukemias(ALL)(CR₁ 4) and 1 had granulocytic sarcoma. Pretreatment regimens mainly included Mel 160 mg/m²+Ara-C 2.0 g/m²+CY 120 mg/kg or TBI 8～10 Gy+CY 120 mg/kg. Results All patients had rapid hemopoietic reconstitution. There was no AHSCT related death. The median follow up duration was 82(12～144) months. Twenty-one of 30 patients were still alive during the analysis. The probabilities of disease-free survival(DFS) at 5 years were significantly different in these two groups: (69±8)% for AHSCT groups and (34±10)% for synchronous intensive chemotherapy groups. Conclusion AHSCT can be safely performed as an important treatment constituent for hematological malignancies.

Key words: autologus, hemopoietic stem cell transplantation, acute leukemia, disease free survival